Peer Reviewed Journals

Study Number

2016 Publications

02-04

Bolla, M., P. Maingon, C. Carrie, S. Villa, P. Kitsios, P. M. Poortmans, S. Sundar, E. M. van der Steen-Banasik, J. Armstrong, J. F. Bosset, F. G. Herrera, B. Pieters, A. Slot, A. Bahl, R. Ben-Yosef, D. Boehmer, C. Scrase, L. Renard, E. Shash, C. Coens, A. C. van den Bergh and L. Collette (2016). “Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.” J Clin Oncol 34(15): 1748-1756. Click here

09-01

Finn, R. S., J. P. Crown, J. Ettl, M. Schmidt, I. M. Bondarenko, I. Lang, T. Pinter, K. Boer, R. Patel, S. Randolph, S. T. Kim, X. Huang, P. Schnell, S. Nadanaciva, C. H. Bartlett and D. J. Slamon (2016). “Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.Breast Cancer Res 18(1): 67. Click here

12-43

Finn, R. S., M. Martin, H. S. Rugo, S. Jones, S. A. Im, K. Gelmon, N. Harbeck, O. N. Lipatov, J. M. Walshe, S. Moulder, E. Gauthier, D. R. Lu, S. Randolph, V. Dieras and D. J. Slamon (2016). “Palbociclib and Letrozole in Advanced Breast Cancer.” N Engl J Med 375(20): 1925-1936. Click here

05-09

Forbes, J. F., I. Sestak, A. Howell, B. Bonanni, N. Bundred, C. Levy, G. von Minckwitz, W. Eiermann, P. Neven, M. Stierer, C. Holcombe, R. E. Coleman, L. Jones, I. Ellis, J. Cuzick and I.-I. investigators (2016). “Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.” Lancet 387(10021): 866-873. Click here

09-03

Harter, P., T. Johnson, D. Berton-Rigaud, S. Y. Park, M. Friedlander, J. M. Del Campo, M. Shimada, F. Forget, M. R. Mirza, N. Colombo, C. Zamagni, J. K. Chan, M. Imhof, T. J. Herzog, D. O’Donnell, F. Heitz, K. King, S. Stinnett, C. Barrett, M. Jobanputra, C. F. Xu and A. du Bois (2016). “BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.” Gynecol Oncol 140(3): 443-449. Click here

09-11

Pinter, T., Z. Klippel, A. Cesas, A. Croitoru, J. Decaestecker, P. Gibbs, Y. Hotko, J. Jassem, G. Kurteva, J. Novotny, S. O’Reilly, T. Salek, M. Reiner, P. K. Morrow, M. R. Choi, S. Whittaker and C. Blanke (2016). “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).” Clin Colorectal Cancer.  Click here

01-04

Press, M. F., G. Sauter, M. Buyse, H. Fourmanoir, E. Quinaux, D. D. Tsao-Wei, W. Eiermann, N. Robert, T. Pienkowski, J. Crown, M. Martin, V. Valero, J. R. Mackey, V. Bee, Y. Ma, I. Villalobos, A. Campeau, M. Mirlacher, M. A. Lindsay and D. J. Slamon (2016). “HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.” J Clin Oncol. Click here

09-03

Pulford, D. J., P. Harter, A. Floquet, C. Barrett, D. H. Suh, M. Friedlander, J. A. Arranz, K. Hasegawa, H. Tada, P. Vuylsteke, M. R. Mirza, N. Donadello, G. Scambia, T. Johnson, C. Cox, J. K. Chan, M. Imhof, T. J. Herzog, P. Calvert, P. Wimberger, D. Berton-Rigaud, M. C. Lim, G. Elser, C. F. Xu and A. du Bois (2016). “Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.” BMC Med Ethics 17(1): 63. Click here

14-13

Reck, M., D. Rodriguez-Abreu, A. G. Robinson, R. Hui, T. Csoszi, A. Fulop, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rangwala, J. R. Brahmer and K.-. Investigators (2016). “Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.” N Engl J Med 375(19): 1823-1833. Click here

06-02

Regan, M. M., P. A. Francis, O. Pagani, G. F. Fleming, B. A. Walley, G. Viale, M. Colleoni, I. Lang, H. L. Gomez, C. Tondini, G. Pinotti, K. N. Price, A. S. Coates, A. Goldhirsch and R. D. Gelber (2016). “Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.” J Clin Oncol 34(19): 2221-2231. Click here

Scott, K., P. J. Hayden, A. Will, K. Wheatley and I. Coyne (2016). “Bortezomib for the treatment of multiple myeloma.” Cochrane Database Syst Rev 4: CD010816. Click here

10-05

Toomey, S., A. J. Eustace, L. B. Pritzker, K. P. Pritzker, J. Fay, A. O’Grady, R. Cummins, L. Grogan, J. Kennedy, D. O’Connor, L. Young, E. W. Kay, N. O’Donovan, W. M. Gallagher, R. Kalachand, J. Crown and B. T. Hennessy (2016). “RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.” J Natl Cancer Inst 108(8). Click here